首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Enhanced distribution and extended elimination of glycyrrhetinic acid in mice liver by mPEG-PLA modified (mPEGylated) liposome.
【24h】

Enhanced distribution and extended elimination of glycyrrhetinic acid in mice liver by mPEG-PLA modified (mPEGylated) liposome.

机译:mPEG-PLA修饰(mPEG化)脂质体可增强小鼠肝中甘草次酸的分布并延长消除时间。

获取原文
获取原文并翻译 | 示例
           

摘要

A rapid and simple method of high-performance liquid chromatography with UV detector for the quantification of glycyrrhetinic acid (GA) in mice plasma and tissues has been developed and validated. With the established assay method, the pharmacokinetic profiles and tissue distribution of GA in different formulations are compared in mice after intravenous administration of the drug (25mg/kg). The results showed that mPEG-PLA modified (mPEGylated) GA liposome (PL-GA) significantly prolonged the mean residence time (MRT) of GA in mice plasma and liver (MRT: 0.43+/-0.13 and 1.72+/-0.11h, respectively) than the normal GA liposome (L-GA) (MRT: 0.23+/-0.01 and 1.07+/-0.31h, respectively) and GA sodium injection (S-GA) (MRT: 0.13+/-0.01 and 0.95+/-0.08h, respectively). Moreover, PL-GA specifically increased GA uptake in liver (AUC(0-infinity,)(liver) value of 1.6-fold and 1.3-fold higher than that for S-GA and L-GA, respectively) and reduced its distribution into other tissues after dosing. Due to these pharmacokinetic properties, it may be promising to develop PL-GA further as a new pharmaceutical preparation for GA on the treatment of various chronic hepatic diseases.
机译:已经开发并验证了一种快速简单的高效液相色谱法和紫外检测器,用于定量测定小鼠血浆和组织中的甘草次酸(GA)。使用已建立的测定方法,比较了静脉内给药(25mg / kg)的小鼠中GA在不同制剂中的药代动力学特征和组织分布。结果表明,mPEG-PLA修饰的(mPEG化)GA脂质体(PL-GA)显着延长了GA在小鼠血浆和肝脏中的平均停留时间(MRT)(MRT:0.43 +/- 0.13和1.72 +/- 0.11h,比普通GA脂质体(L-GA)(分别为MRT:0.23 +/- 0.01和1.07 +/- 0.31h)和GA钠注射液(S-GA)(MRT:0.13 +/- 0.01和0.95+ /-0.08h)。此外,PL-GA特异性增加了肝脏对GA的摄取(AUC(0-infinity,)(肝脏)值分别比S-GA和L-GA高1.6倍和1.3倍),并减少了其在肝脏中的分布给药后其他组织。由于这些药代动力学性质,可能有希望进一步开发PL-GA作为用于治疗各种慢性肝病的GA的新药物制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号